Management Of Non Muscle Invasive Bladder Cancer

This book covers the latest advances in non-muscle invasive bladder cancer care. It provides a review of the available evidence base for the efficacy of a range of therapeutic techniques, diagnostic procedures and risk factors. Management of Non-Muscle Invasive Bladder Cancer features detailed guidance in uniformly formatted chapters on how to properly apply a range of available therapeutic treatments relevant for patient care. It is a valuable resource for all trainee and practising medical professionals who treat these patients.

Invasive bladder tumors affect the muscle wall, and have a propensity to metastasize and spread to other areas of the body, and are more likely to be fatal. This book presents state-of-the-art diagnoses and treatments available for bladder cancer that has metastasised into the body. A thorough review of current practice is presented in a full color volume with more than 40 tables and 50 illustrations. The book offers a comprehensive review of the subject, covering epidemiology, screening, diagnostic factors, surgery, chemotherapy and post-operative monitoring. Most chapters are jointly written by a basic researcher and a clinician.

Neoadjuvant chemotherapy with cisplatin-based regimens improved survival in patients with muscle-invasive bladder cancer, and extended lymph node dissection during cystectomy might be more effective than standard lymph node dissection for improving survival. More research is needed to clarify the effectiveness of bladder-preserving therapies versus radical cystectomy and define patient subgroups in which such therapies may be an option.

Of the three types of bladder cancer, Non-Muscle Invasive Bladder Cancer (NMIBC) is the most common form and is diagnosed in over 70% of cases. This issue of the Urologic Clinics focuses on NMIBC and includes articles on periopertive chemotherapy, office fulguration, TURBT, surveillance strategies, and radiation therapy in type-1 tumors.

This book covers the latest advances in non-muscle invasive bladder cancer care. It provides a review of the available evidence base for the efficacy of a range of therapeutic techniques, diagnostic procedures and risk factors. Management of Non-Muscle Invasive Bladder Cancer features detailed guidance in uniformly formatted chapters on how to properly apply a range of available therapeutic treatments relevant for patient care. It is a valuable resource for all trainee and practising medical professionals who treat these patients.

Bladder cancer is one of the most exciting urological cancers. It exists in two forms - non-muscle-invasive (NMI) and muscle-invasive (MI) disease. The difference in the clinical picture has been the focus of significant research in defining the molecular characteristics of urothelial cancer (UC) of the bladder. This book provides an overview of the most hotly debated areas in bladder cancer. Authors have focused on the emerging role of markers for NMI UC and various ways of improving the efficacy of current chemotherapy in the first section. The second section has focused on the surgical aspects of MI UC. Two major areas of debate - the role of pelvic lymph node dissection and genital sparing surgery - are discussed in this section.

Of the three types of bladder cancer, Non-Muscle Invasive Bladder Cancer (NMIBC) is the most common form and is diagnosed in over 70% of cases. This issue of the Urologic Clinics focuses on NMIBC and includes articles on periopertive chemotherapy, office fulguration, TURBT, surveillance strategies, and radiation therapy in type-1 tumors.

Upper Tract Urothelial Carcinoma represents the first book of its kind to be dedicated solely to UTUC. It's aim is to improve understanding and eventually care of a disease that is greatly understudied and underappreciated, yet commonly dealt with by many medical and urologic oncologists. The volume features new data regarding genetic susceptibility, gene expression studies and causative factors; contemporary concepts and controversies regarding diagnosis and staging of UTUC; prediction tools and their value in treatment decisions within each disease stage and patient selection and treatment options such as endoscopic management, distal ureterectomy, radical nephroureterectomy and chemotherapy. Up-to-date information regarding boundaries of surgical resection, indication and extent of lymphadenectomy is covered as well as the role of perioperative/neoadjuvant chemotherapy in patients with high-risk UTUC. Upper Tract Urothelial Carcinoma will be of great value to all Urologists, Medical Oncologists and fellows in Urologic Oncology as well as upper level residents in training in Urology and Medical Oncology.